MVA-BN-RSV
AXP000204.1 · Vaccine
- Platform
- MVA-BN
- Targets
- RSV F; RSV G (A and B); RSV N; RSV M2-1
- Originator
- Bavarian Nordic
- Sponsor
- Bavarian Nordic
Names
| Name | Type | Source |
|---|---|---|
| MVA-BN-RSV | preferred name, code | curator, press |
| MVA-RSV ambiguous | synonym | paper |
| VANIR ambiguous | synonym | press |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA-BN
- Replication
- non replicating
- Modifications
- five RSV antigen cassettes inserted into MVA-BN
- Transgenes
- RSV F (A long), RSV G (subtype A, A2), RSV G (subtype B), RSV N (A2), RSV M2-1 (A2)
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05238025 | MVA-BN-RSV Vaccine Trial | Terminated | Phase 3 | 2022-04-19 | 2023-06-29 | 20419 | Respiratory Syncytial Virus Infections |
| NCT04752644 | Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults | Completed | Phase 2 | 2021-02-22 | 2021-06-17 | 73 | RSV Infection |
| NCT02873286 | RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults | Completed | Phase 2 | 2016-09 | 2018-12 | 420 | Respiratory Syncytial Virus Infections |
| NCT02864628 | RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. | Withdrawn | Phase 1 | 2016-09 | 2017-10-27 | 0 | Respiratory Syncytial Virus Infections |
| NCT02419391 | Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine | Completed | Phase 1 | 2015-08 | 2015-12 | 63 | Respiratory Syncytial Virus Infections |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT01805921 | RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. | Completed | Phase 1 | 2013-05 | 2015-08 | 72 | Respiratory Syncytial Virus Infections | name in intervention: MVA-RSV |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39461302 | A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study. | Vaccine | 2024 | cited by trial NCT05238025 |
| PMID 37079393 | Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine. | The Journal of infectious diseases | 2023 | cited by trial NCT04752644 |
| PMID 32726422 | Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine. | The Journal of infectious diseases | 2021 | cited by trial NCT02873286 |
| PMID 32057576 | Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial. | Vaccine | 2020 | name in abstract: MVA-BN-RSV |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 26510727 | Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. | BMJ open | 2015 | name in title: MVA-RSV |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40265347 | Analyzing Differences in Viral Dynamics Between Vaccinated and Unvaccinated RSV Patients. | Epidemiologia (Basel, Switzerland) | 2025 | name in abstract: MVA-BN-RSV |
| PMID 36280532 | Development of mRNA vaccines against respiratory syncytial virus (RSV). | Cytokine & growth factor reviews | 2022 | name in abstract: MVA-BN-RSV |
Notes
MVA-BN encoding five RSV antigens: fusion protein F (RSV-A long), glycoprotein G of subtypes A (A2) and B, nucleoprotein N and transcription elongation factor M2-1 (A2). Single-dose phase 3 VANIR trial in >20,000 adults aged 60+ missed a co-primary endpoint (42.9% efficacy against disease with 3+ symptoms vs 59% with 2+), reported 22 July 2023; the programme was discontinued. Route not recorded here.
How to cite
MVA-BN-RSV (AXP000204.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000204.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.